Professor, Human Biology and Public Health Sciences Division
Associate Director for Education and Career Enhancement
Endowed Chair of Graduate Studies
Affiliate Professor, University of Washington
Director, Office of Education and Training, Fred Hutch/UW Cancer Consortium
Director, Viral Pathogenesis and Evolution Training Program
I study the evolution of human antibody responses directed against HIV-1 infection. We sequence antibody genes from B cells within longitudinal patient blood samples to estimate how their HIV-specific antibody lineages developed.
I am interested in defining which interferon-stimulated genes are involved in the restriction of lentiviruses.
I am currently working on isolating and characterizing HIV-specific broadly neutralizing antibodies from women who are superinfected with HIV-1. Superinfection with two distinct viral strains generates a broad polyclonal repertoire of neutralizing antibodies targeted to HIV. Understanding how these antibodies evolve and develop may assist future vaccine design.
I am interested in flavivirus biology and circulation in Africa. I will develop methodology to surveil global presence of Zika and other flaviviruses with high specificity, and will investigate genes that govern innate immune responses during infection.
I am interested in studying the function and epitope of antibodies that potentially mediate protection from HIV, with the goal of informing HIV vaccine design.
I am interested in applying high-throughput techniques to identify interferon-induced genes that are potent inhibitors of early viral infection and replication (restriction factors).
I am broadly interested in host-pathogen interactions and the evolution of the immune system to target human pathogenic viruses. Specifically, understanding the natural evolution of broadly neutralizing antibodies in HIV-1 infected individuals to inform vaccine development.
I am interested in studying mechanisms of innate and adaptive immunity to emerging viruses, including Zika virus and SARS-CoV-2.
I am interested in studying the evolution of both neutralizing and non-neutralizing antibodies in HIV-1 infected individuals. I would also like to better understand how effector functions influence whether a given antibody will be beneficial or detrimental in the context of HIV infection.
I am interested in the intersection of microbiology and global public health, particularly as it pertains to viruses. I believe that understanding disease from the molecular level all the way to the population health level can help us achieve a healthier world.
I am interested in how CRISPR-Cas9 technology can be used to study the innate immune response to HIV and SARS-CoV-2.
I perform Gen Probe QC HIV viral RNA loads and population based sequencing for resistant mutations for women on ARV for the QRS cohort. I’ve also been involved with neutralization assays using the PBMC and TZM methods for PBMC and 293T-passaged chimeras with monoclonal antibodies.
I am interested in studying the diversity and evolution of HIV-1 in Kenyan infants to understand the timing of infection.
My current work is focused on isolating and characterizing HIV-specific broadly neutralizing antibodies isolated from infants and superinfected indviduals.
Co-mentored with Erick Matsen
Co-mentored with Erick Matsen